The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients,Journal of Clinical Laboratory Analysis

当前位置： X-MOL 学术 › J. Clin. Lab. Anal. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients
Journal of Clinical Laboratory Analysis ( IF 2.6 ) Pub Date : 2023-10-03 , DOI: 10.1002/jcla.24969
Hanaa Wanas _{1,

2} , Mai Hamed Kamel ₃ , Emad Adel William ₄ , Tarek Fayad ₅ , Mohamed Essmat Abdelfattah ₅ , Hossein Mostafa Elbadawy ₂ , Emily Samir Mikhael ₃

Affiliation

Tacrolimus (TAC) is the mainstay of immunosuppressive regimen for kidney transplantations. Its clinical use is complex due to high inter-individual variations which can be partially attributed to genetic variations at the metabolizing enzymes CYP3A4 and CYP3A5. Two single nucleotide polymorphisms (SNPs), CYP3A4*22 and CYP3A5*3, have been reported as important causes of differences in pharmacokinetics that can affect efficacy and/or toxicity of TAC.

中文翻译：

CYP3A4和CYP3A5基因变异对埃及活体肾移植患者他克莫司治疗的影响

他克莫司（TAC）是肾移植免疫抑制方案的支柱。由于个体间差异较大，其临床应用很复杂，这部分归因于代谢酶 CYP3A4 和 CYP3A5 的遗传变异。据报道，两种单核苷酸多态性 (SNP) CYP3A4*22 和 CYP3A5*3 是药代动力学差异的重要原因，可影响 TAC 的功效和/或毒性。

更新日期：2023-10-03

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南